Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 107 clinical trials
5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.

-fluorouracil, leucovorin, irinotecan, temozolomide and bevacizumab in patients with MGMT silenced and MSS mCRC. The study will consist in a dose-escalation assessment of the safety of the treatment in

  • 3 views
  • 23 Apr, 2022
  • 1 location
Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine and Nab-Paclitaxel (MP-PDAC-01)

uncontrolled CNS metastases (patients who require steroids should be on a stable or decreasing dose for at least 2 weeks) Subjects who have any contraindications for 5-FU, leucovorin, or oxaliplatin

biliary stents
folfox
paclitaxel
aptt
adenocarcinoma
  • 1 views
  • 29 Jun, 2022
  • 1 location
FOLFIRI as Second Line Chemotherapy for Metastatic Esophageal Carcinoma

This phase study was designed to evaluate the efficacy and safety of FOLFIRI as second-line treatment for metastatic esophageal carcinoma.

  • 7 views
  • 23 Jan, 2021
  • 1 location
Study of Immunotherapy Combined With Chemotherapy in Locally Advanced and Metastatic Pancreatic Cancer

To evaluate the efficacy of PD-L1/CTLA4 BsAb for the second line treatment and the combination with chemotherapy for the first line treatment in pancreatic cancer

  • 0 views
  • 02 Mar, 2022
  • 1 location
FOLFIRINOX vs FLOT Chemotherapy for Resectable Gastric or Esophagogastric Junction Adenocarcinoma

before and after surgery. One half of the patients gets 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin and Docetaxel (FLOT), the others 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin and Irinotecan

docetaxel
adenocarcinoma
neutrophil count
irinotecan
oxaliplatin
  • 9 views
  • 22 Apr, 2021
  • 1 location
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer (FORTITUDE-102)

The main objective of Part 1 is to evaluate the safety and tolerability of bemarituzumab plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) and nivolumab. The main objective Part

immunostimulants
cancer chemotherapy
adenocarcinoma
adjuvant therapy
neutrophil count
  • 0 views
  • 09 Jun, 2022
  • 14 locations
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

deficient deoxyribonucleic acid (DNA) mismatch repair. Drugs used in combination chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor

tumor cells
hysterectomy
antibiotics
stage iii colon cancer
corticosteroids
  • 1144 views
  • 28 Jun, 2022
  • 546 locations
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Leucovorin decreases the toxic effects of methotrexate. Giving

lymphoblastic lymphoma
doxorubicin
flow cytometry
leukemia
calcium
  • 92 views
  • 18 Jun, 2022
  • 111 locations
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine

lymphoblastic lymphoma
doxorubicin
daunorubicin
flow cytometry
cns leukemia
  • 56 views
  • 27 May, 2022
  • 116 locations
Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

This is a Global Study of Neoadjuvant-Adjuvant Durvalumab or Placebo and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Patients with Resectable Gastric and Gastroesophageal Cancer (GC/GEJC) (MATTERHORN).

cancer
oxaliplatin
monoclonal antibodies
adenocarcinoma
immunoglobulin
  • 16 views
  • 13 Jun, 2022
  • 136 locations